4 research outputs found
Rapid And Durable Responses With The Syk/Jak Inhibitor Cerdulatinib In A Phase 2 Study In Relapsed/Refractory Follicular Lymphoma—Alone Or In Combination With Rituximab
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149541/1/hon30_2629.pd